Article
Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes.
The protein journal - 1 Jan 2013
Elfiky Abdo A, Elshemey Wael M, Gawad Wissam A, Desoky Omar S
Abstract excerpt
The current available treatment for hepatitis C virus (HCV)-the causative of liver cirrhosis and development of liver cancer-is a dual therapy using modified interferon and ribavirin. While this regimen increases the sustained viral response rate up to 40-80 % in different genotypes, unfortunately, it is poorly tolerated by patients. PSI-7977, a prodrug for PSI-7409, is a Non-Structural 5b (NS5b) polymerase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
